Sonnet BioTherapeutics

graphic of cancer calls
Biotech

J&J-partnered Sonnet halts work on bispecific, hunts for allies

In these financially straitened times, biotechs need to be increasingly ruthless about which programs they can afford to keep funding.
James Waldron Dec 16, 2022 10:35am